УДК 61 Медицина. Охрана здоровья
Терапия генно-инженерными биологическими препаратами – это новый подход к лечению аутоиммунных и аллергических заболеваний в пульмонологии, гематологии, гастроэнтерологии, неврологии, онкологии. Сегодня благодаря им удается кардинально улучшить качество жизни пациентов с такими заболеваниями, которые раньше считались неизлечимыми и плохо контролировались. В ряде случаев применение терапии позволяет достигать длительной и стойкой ремиссии. В статье рассмотрен ряд генно-инженерных биологических препаратов, используемых в различных терапевтических направлениях и механизмы их действия.
генно-инженерные биологические препараты, бронхиальная астма, омализумаб, квилизумаб, лигелизумаб, лебрикизумаб, тралокинумаб, дупилумаб, меполизумаб, бенрализумаб, февипипрант
1. Зырянов С.К., Бутранова О.И. Генно-инженерно-биологические препараты в терапии бронхиальной астмы: современные достижения. Пульмонология. 2018; 28
2. Menzella F., Galeone C., Bertolini F. et al. Innovative treat-ments for severe refractory asthma: how to choose the right option for the right patient? J. Asthma Allergy. 2017;
3. Oettgen H.C. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J. Allergy Clin. Immunol. 2016; 137
4. Braunstahl G.J., Chen C.W., Maykut R. et al. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir. Med. 2013; 107.
5. Harris J.M., Maciuca R., Bradley M.S. et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir. Res. 2016;
6. Gauvreau G.M., Arm J.P., Boulet L.P. et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol. 2016; 138
7. Hanania N.A., Noonan M., Corren J. et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015; 70
8. Scheerens H., Arron J.R., Zheng Y. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy. 2014; 44
9. Hanania N.A, Korenblat P., Chapman K.R. et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 2016; 4
10. Panettieri R.A. Jr, Wang M., Braddock M. et al. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018; 10
11. Slager R.E., Otulana B.A., Hawkins G.A. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J. Allergy Clin. Immunol. 2012; 130
12. Shirley M. Dupilumab: First Global Approval. Drugs. 2017; 77 Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380
13. Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380
14. Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371
15. Varricchi G., Bagnasco D., Ferrando M. et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther. Adv. Respir. Dis. 2017; 11
16. Pelaia C., Vatrella A., Bruni A. et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des. Devel. Ther. 2018; 12
17. Erpenbeck V.J., Popov T.A., Miller D. et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm. Pharmacol. Ther. 2016
18. Kang-Moon Lee, Yoon Tae Jeen, Ju Yeon Cho, Chang Kyun Lee, Ja-Seol Koo, Dong Il Park, Jong Pil Im, Soo Jung Park, You Sun Kim, Tae Oh Kim, Suck-Ho Lee, Byung Ik Jang, Ji Won Kim, Young Sook Park, Eun-Soo Kim, Chang Hwan Choi, Hyo Jong Kim. Efficacy, Safety, and Predictors of Response to Infliximab Therapy for Ulcerative Colitis.A Korean Multicenter Retrospective Study.J Gastroenterol Hepatol. 2013;28(12):1829-1833.
19. Sartor RB, Hoentjen F. Proinflammatory cytokines and signaling pathways in intestinal innate immune cells. Mucosal Immunology. 2005;30:681-701.
20. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333
21. Harousseau JL. Interet clinique de l'interferon alpha dans le traitement des hemopathies malignes.Presse Med 1997; 26: 857 - 9.
22. Kieseier BC. The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis. CNS Drugs. 2011;25
23. Francis G, Kappos L, O’Connor P, Collins W, Tang D, Mercier F, Cohen JA. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler J. 2014;20
24. Immune system resetting and long-term remission in multiple sclerosis: rationale and possibilities an EXCEMED Satellite Symposium at the 3rd EAN Congress/EXCEMED [Электронный ресурс]. Дата обращения: 25.12.18. URL: https://www.excemed.org/live-events/immune-systemresetting-and-long-term-remission-multiple-sclerosis-rationale-andpossibilities-excemed-satellite-symposium-3rd-ean-congress
25. Wiendl H, Bourdette D, Ciccarelli O. Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis? Neurology. 2017;89 11
26. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2)
27. McCall B. Alemtuzumab to be restricted pending review, says EMA. Lancet. 2019;393(10182):1683. https://doi.org/10.1016/S0140-6736(19)30935-3
28. Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28-35. https://doi.org/10.1097/WNF.0b013e318204cd90
29. Саллес Г. И др. Ритуксимаб при В-клеточных гематологических злокачественных новообразованиях: обзор 20-летнего клинического опыта.Adv.2017 PMID 28983798
30. Тарасова Л.В., Бусалаева Е.И., Цыганова Ю.В., Жудылина Н.В., Матысякевич И.Д. Опыт применения ведолизумаба при язвенном колите (клинический случай). Доказательная гастроэнтерология. 2020;9(3):77-82. https://doi.org/10.17116/dokgastro2020903177
